Vaccine for the prevention of the recurrence HER2/neu expressing cancer
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsGeorge Peoples, Sathibalan Ponniah
Life of this patent
Estimating the term…
Abstract
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
Claims23
A method of inducing protective or therapeutic immunity against recurrence of a HER2/neu expressing tumor in a subject, wherein the tumor is characterized as having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression, said method comprising administering to the subject an effective amount of a composition comprising a pharmaceutically effective carrier and a peptide having the amino acid sequence SEQ ID NO:2.
A method of inducing protective or therapeutic immunity against breast cancer recurrence in a subject having an a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression, said method comprising administering to the subject an effective amount of a composition comprising a pharmaceutically effective carrier and a peptide having the amino acid sequence SEQ ID NO:2.
A method of inducing protective or therapeutic immunity against recurrence of HER2/neu expressing tumor in a subject, wherein the tumor is characterized as a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression, said method comprising administering to the subject an effective amount of a composition comprising a pharmaceutically effective carrier and a peptide having the amino acid sequence SEQ ID NO:2 or a variant thereof, wherein immunity is established by a statistically significant increase in the presence of CD8+ cells specific for the peptide in peripheral blood mononuclear cells of the subject when compared to pre-vaccine levels.
Dependencies are inferred from the claim text.